B3 WR disease.

B4 14 (amended). A method according to claim 13, wherein the compound enhances or inhibits the growth of a subgroup of T-cells selected from the group consisting of inflammatory, regulatory or cytotoxic T-cells.

B5 17 (amended). A method according to claim 1, wherein the T-cells are inflammatory T-cells.

B6 19 (amended). A method according to claim 18, wherein the inflammatory T-cells are cells contributing in a type 1 inflammatory response producing IFNγ and TNFα.

B7 22 (amended). A method according to claim 21, wherein the inflammatory T-cells are cells contributing in a type 2 inflammatory response producing IL-4 or IL-5.

B8 24 (amended). A method according to claim 17, wherein the disease is mediated or partially mediated by type 1 or type 2 inflammatory T-cells.

B9 25 (amended). A method according to claim 1, wherein the T-cells are regulatory T-cells.

B10 29 (amended). A method according to claim 25, wherein the disease is mediated or partly mediated by type 2 inflammatory T-cells.

B11 34 (amended). A method according to claim 1, wherein the T-cells are cytotoxic T-cells.

B12 37 (amended). A method according to claim 34, wherein the one or more additional compounds is selected from GM-CSF, caspase inhibitors, Z-VAD, α-CD95, IL-10, IL-12, IL-16, and functionally similar compounds.

B13 39 (amended). A method according to claim 34 wherein the disease is selected from the group consisting of malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer, hepatic carcinoma, and cutaneous lymphoma.

B14 40 (amended). A disease associated, antigen activated continuous T-cell line obtained by a method according to claim 1.

B15 44 (amended). A vaccine comprising a continuous, disease associated, antigen activated T-cell line according to claim 41.

B16 52 (amended). A method for the treatment, alleviation or